Fig. 7: Pharmacokinetic properties of ENT1 inhibitors following subcutaneous administration.
From: Design of an equilibrative nucleoside transporter subtype 1 inhibitor for pain relief
a PWT after subcutaneous (s.c.) injections of dilazep (n = 9, 5 males and 4 females, 3 × 30 mg/kg) and JH-ENT-01 (n = 7, 5 males and 2 females, 3 × 30 mg/kg) in mice with STZ-induced diabetic neuropathy. Arrows indicate three s.c.. injections on days 8, 10, and 12. Note that all mice survived after the s.c. injections. Two-way ANOVA followed by Bonferroni posthoc comparison (P = 0.027 for overall comparison between JH-ENT-01 and dilazep. * P < 0.05, JH-ENT-01 vs. dilazep at 1 h after 3rd injection). b Pharmacokinetic profile of JH-ENT-01 and dilazep in plasma, following a single s.c. injection of JH-ENT-01 (30 mg/kg) and equimolar amount of dilazep (n = 3 male mice per time point). All data were expressed as mean ± s.e.m.
